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ER-WCPT16 Abstract 
Use of an 'adapted Zelen' design in a randomised controlled trial of a 
physiotherapist-led exercise intervention in patients with myeloma 
Relevance: 
This report outlines methodology that will interest academic and clinical physiotherapists 
who seek to increase the strength of evidence-base through use of intervention trials. 
Purpose:  
Contamination of control groups (CG) can introduce bias and threaten internal validity in 
exercise intervention trials, where blinding of participants to their allocation is not possible. 
Participants in cancer exercise interventions are often highly motivated and randomisation 
to a CG may lead to distress. Additionally, if participants believe that exercise ‘may’ be 
beneficial, those randomised to the CG may seek out and enrol on other exercise 
programmes, which could dilute the intervention effect. Ways of minimising contamination 
in CG include offering the intervention to the controls after the intervention group (IG) ‘wait 
list control’, or offering alternative intervention. However, these methods require additional 
levels of funding and staffing that are not always possible. Another method which could 
minimise contamination is use of the ‘Zelen’ design, reversing the traditional research 
process to conduct randomisation prior to consent. The Zelen design has been used 
successfully in behavioural and exercise interventions trials and was adapted to a two-
stage consent design for this study.  
Approach/Evaluation: 
An 'adapted Zelen' design involving a double consent process was employed in a 
randomised control trial (RCT) of a physiotherapist-led exercise intervention in patients 
with myeloma in stable plateau phase. The study is a RCT embedded within a lifestyle 
cohort study.  
Participants were initially approached and consented to a cohort study aimed at 
understanding lifestyle behaviours and their relationship with fatigue and quality of life. 
Once consented to the cohort study and baseline assessments completed, participants 
were randomised to either an IG or 'remain in cohort' (control) group. Those allocated to 
the intervention were then approached again about a second study evaluating an exercise 
intervention, and consented for a second time. Those allocated to the CG were not 
informed about the exercise trial or randomisation process. Full ethical approval for this 
method was provided by the NRES Committee London – Queen Square (13/LO/1105). 
Outcome: 
Marked differences in uptake between cohort and IG were evident. Initial uptake to the 
study was strong with 66.67% of those approached being enrolled. Uptake, however, was 
lower in those randomised and approached for the exercise trial (44.74%). Detailed 
experiences of using this design in practice will be discussed, including blinding, 
considerations for analysis (intention to treat and per protocol analysis), and adjustments 
to study design. 
Discussion & Conclusions: 
This approach may be a useful way to avoid contamination in exercise or therapy 
intervention trials, where blinding to group allocation is impossible. Future studies using 
this design should consider ways of ascertaining participants' likelihood of agreeing to the 
intervention being tested prior to approach for a cohort study, without introducing selection 
bias. 
This study will conclude in June 2017 when full statistical analysis of the intervention and 
the usefulness of this 'adapted Zelen' approach will be known.  
Impact & Implications: 
 This report highlights methodological considerations for physiotherapy interventions 
trials were treatment effect is at risk from contamination of controls. 
 Development of methods to strengthen the physiotherapy evidence base are key to 
promoting the profession. 
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